Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd Sells 1,500 Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total value of $185,625.00. Following the completion of the transaction, the chief executive officer now owns 440,307 shares of the company’s stock, valued at $54,487,991.25. This trade represents a 0.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Jazz Pharmaceuticals Trading Down 8.9 %

Shares of NASDAQ JAZZ opened at $110.04 on Friday. The stock has a market cap of $6.68 billion, a price-to-earnings ratio of 15.50, a PEG ratio of 1.04 and a beta of 0.42. The business has a 50 day simple moving average of $132.27 and a 200 day simple moving average of $122.99. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06.

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. IFP Advisors Inc acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $25,000. Quadrant Capital Group LLC raised its holdings in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 101 shares in the last quarter. Elequin Capital LP lifted its position in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 183 shares during the last quarter. CoreFirst Bank & Trust bought a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth about $28,000. Finally, Allianz SE acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $29,000. 89.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

JAZZ has been the subject of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Morgan Stanley reiterated an “overweight” rating and set a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, Piper Sandler reiterated an “overweight” rating and set a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.